The current Coronavirus 2019 (COVID-19) pandemic has shown us that the pharmaceutical research community can organize and administer large nonprofit clinical trials (RECOVERY and SOLIDARITY) and achieve the swift development of common, unpatentable drugs for a new indication: in this case an old, inexpensive drug, dexamethasone, for COVID-19. Why is it that such nonprofit efforts are so rare and are not organized as a systemic, routine part of drug development in the public interest? Based on my own experience with repurposing the alcohol-abuse drug disulfiram (Antabuse) for cancer, I identify at least four serious deadlocks to development of nonprofit drugs. All of these obstacles should be addressed to leverage the potential of the COVID-19 pandemic for better future healthcare systems in all countries around the world.

Palacky University Olomouc Czech Republic

Zobrazit více v PubMed

WHO . WHO; Geneva: 2017. Ten years in Public Health, 2007-2017: Report by Dr. Margaret Chan, Director-General, World Health Organization.

OECD . OECD Publishing; Paris: 2009. Fiscal Sustainability of Health Systems: Bridging Health and Finance Perspectives.

EC. Making medicines more affordable. https://ec.europa.eu/health/human-use/strategy/affordable_medicines_en [accessed May 25, 2022].

Collins F.S. Mining for therapeutic gold. Nat Rev Drug Discov. 2011;10:397. PubMed PMC

EMA. EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation. http://www.ema.europa.eu/en/news/ema-endorses-use-dexamethasone-covid-19-patients-oxygen-mechanical-ventilation [accessed May 25, 2022].

Ledford H. Coronavirus breakthrough: dexamethasone is the first drug shown to save lives. Nature. 2020;582:469. PubMed

Begley C.G., Ellis L.M. Drug development: raise standards for preclinical research. Nature. 2012;483:531–533. PubMed

Harris R. Basic Books; New York: 2017. Rigor Mortis: How Sloppy Science Creates Worthless Cures, Crushes Hope, and Wastes Billions.

Kane P.D., Kimmelman J. Is preclinical research in cancer biology? Elife. 2021;10 PubMed PMC

Cvek B. Targeting malignancies with disulfiram (Antabuse): multidrug resistance, angiogenesis, and proteasome. Curr Cancer Drug Targets. 2011;11(3):332–337. PubMed

Reinhardt S., Stoye N., Luderer M., Kiefer F., Schmitt U., Lieb K., et al. Identification of disulfiram as a secretase-modulating compound with beneficial effects on Alzheimer’s disease hallmarks. Sci Rep. 2018;8:1329. PubMed PMC

Dalecki A.G., Haeili M., Shah S., Speer A., Niederweis M., Kutsch O., et al. Disulfiram and copper ions kill Mycobacterium tuberculosis in a synergistic manner. Antimicrob Agents Chemother. 2015;59:4835–4844. PubMed PMC

Potula H.H.S.K., Shahryari J., Inayathullah M., Malkovskiy A.V., Kim K.M., Rajadas J. Repurposing disulfiram (tetraethylthiuram disulfide) as a potential drug candidate against Borrelia burgdorferi in vitro and in vivo. Antibiotics (Basel) 2020;9:633. PubMed PMC

Hu J.J., Liu X., Xia S., Zhang Z., Zhang Y., Zhao J., et al. FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nat Immunol. 2020;21:736–745. PubMed PMC

Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289–293. PubMed

Skrott Z., Mistrik M., Andersen K.K., Friis S., Majera D., Gursky J., et al. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature. 2017;552(7684):194–199. PubMed PMC

Pearson H. How COVID broke the evidence pipeline. Nature. 2021;593:182–185. PubMed

Niburski K., Niburski O. Impact of Trump’s promotion of unproven COVID-19 treatments and subsequent internet trends: observational study. J Med Internet Res. 2020;22 PubMed PMC

Kim A.H.J., Sparks J.A., Liew J.W., Putman M.S., Berenbaum F., Duarte-García A., et al. A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. Ann Intern Med. 2020;172:819–821. PubMed PMC

Rome B.N., Avorn J. Drug evaluation during the COVID-19 pandemic. N Engl J Med. 2020;382:2282–2284. PubMed

WHO Solidarity Trial Consortium Repurposed antiviral drugs for COVID-19. Interim WHO Solidarity trial results. N Engl J Med. 2021;384:497–511. PubMed PMC

The Recovery Collaborative Group Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384:693–704. PubMed PMC

Sundar S., Jha T.K., Thakus C.P., Sinha P.K., Bhattacharya S.K. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med. 2007;356:2571–2581. PubMed

Cvek B. Nonprofit drugs as the salvation of the world’s healthcare systems: the case of Antabuse (disulfiram) Drug Discov Today. 2012;17:409–412. PubMed

Bertolini F., Sukhatme V.P., Bouche G. Drug repurposing in oncology – patient and health systems opportunities. Nat RevClin Oncol. 2015;12:732–742. PubMed

Dufour P., Lang J.M., Giron C., Duclos B., Haehnel P., Jaeck D., et al. Sodium dithiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study. Biotherapy. 1993;6:9–12. PubMed

Nechushtan H., Hamamreh Y., Nidal S., Gotfried M., Baron A., Shalev Y.I., et al. A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer. Oncologist. 2015;20:366–367. PubMed PMC

Lynch H.F., Zettler P.J., Sarpatwari A. Promoting patient interests in implementing the federal Right to Try Act. JAMA. 2018;320:869–870. PubMed

Beaver J.A., Howie L.J., Pelosof L., Kim T., Liu J., Goldberg K.B., et al. A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review. JAMA Oncol. 2018;4:849–856. PubMed

Prasad V. Do cancer drugs improve survival or quality of life? BMJ. 2017;359:j4528. PubMed PMC

Cvek B. Searching for positive side effects of common drugs. Trends Pharmacol Sci. 2017;38:111. PubMed

Goldberg A.L. Development of proteasome inhibitors as research tools and cancer drugs. J Cell Biol. 2012;199:583–588. PubMed PMC

Cvek B. Proteasome inhibitors. Prog Mol Biol Transl Sci. 2012;109:161–226. PubMed